Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III

doi:10.1016/0021-9150(89)90221-9

Atherosclerosis

Volume 78, Issues 2–3, August 1989, Pages 167-182

https://doi.org/10.1016/0021-9150(89)90221-9 Get rights and content

Abstract

Fenofibrate (300 mg daily) was given to 9 subjects (7 men, 2 women) with dysbetalipoproteinemia type III. The treatment brought about important plasma level reductions in cholesterol (−35%), triglycerides (−56%), VLDL-cholesterol (−63%) and VLDL-triglycerides (−59%). The VLDL-C/TG ratio, which was 0.40 before treatment, was 0.30 after 4 weeks of fenofibrate, still suggestive of type III. LDL-C, when measured by conventional methods, was unchanged but isolation of the IDL (1.006–1.019 g/ml) fraction from the 1.006 g/ml infranatant revealed that true LDL-C levels actually increased in 6 individuals while IDL-C decreased considerably. The total HDL-C increase was mostly due to a 33% HDL₃-C change. Apolipoprotein levels were considerably modified, notably apo B, C-III and E which were decreased, as well as the lipoprotein particles containing combinations of these apolipoproteins, namely LpE : B and LpC-III : B. Apo A-I was slightly modified as LpA-I : A-II particle levels increased and LpA-I decreased. There were marked compositional modifications of apo B-containing lipoproteins which corresponded to changes of the whole lipoprotein profile. Some abnormal classes of lipoproteins (e.g., β-VLDL, dense LDL), characteristic of this disease, tended to disappear and were in some cases replaced by material of different size and density.

References (56)

A. Chait et al.
Type-III hyperlipoproteinaemia (“Remnant removal disease”)
Lancet
(1977)
M. Berman et al.
Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects
J. Lipid Res.
(1978)
M.F. Reardon et al.
The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia
Metabolism
(1982)
J.C. Fruchart et al.
Effect of fenofibrate treatment on type III hyperlipoproteinemia
Am. J. Med.
(1987)
L.I. Gidez et al.
Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure
J. Lipid Res.
(1982)
P. Gambert et al.
Alterations of HDL cholesterol distribution induced by incubation of human serum
Biochim. Biophys. Acta
(1982)
J.R. Patsch et al.
Separation of the main lipoprotein density classes from human plasma by rate-zonal ultracentrifugation
J. Lipid Res.
(1974)
O.H. Lowry et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951)
E. Koren et al.
Quantitative determination of human plasma apolipoprotein A-I by a noncompetitive enzyme-linked immunosorbent assay
Clin. Chim. Acta
(1985)
M. Koffigan et al.
Quantification of human apolipoprotein E in plasma and lipoprotein subfractions by a noncompetitive enzyme immunoassay
Clin. Chim. Acta
(1987)

D. Bouthillier et al.

Apolipoprotein E phenotyping with a single gel method-application to the study of informative matings

J. Lipid Res.

(1983)

S. Salmon et al.

Monoclonal antibodies to low density lipoproteins in “ELISA” and immunoprecipitation technics

Biochem. Biophys. Res. Commun.

(1984)

I. Luyeye et al.

Human apolipoprotein B. Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay

Clin. Biochem.

(1988)

S. Rossner et al.

Fenofibrate therapy of hyperlipoproteinemia. A dose-response study and a comparison with clofibrate

Atherosclerosis

(1981)

G. Baggio et al.

Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias

Pharmacol. Res. Commun.

(1986)

W.R. Hazzard et al.

Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia

Metabolism

(1981)

G. Schmitz et al.

Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes

J. Lipid Res.

(1985)

A.P. Goldberg et al.

Adipose tissue lipoprotein lipase activity in type III hyperlipoproteinemia

Metabolism

(1979)

B.H. Chung et al.

Resistance of a very low density subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low-density lipoprotein density fraction

J. Lipid Res.

(1983)

R.M. Krauss

Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease

Am. Heart J.

(1987)

J.R. Patsch et al.

Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia

Am. J. Med.

(1977)

M.J. Mellies et al.

Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia

Atherosclerosis

(1987)

S. Eisenberg

Lipoprotein abnormalities in hypertriglyceridemia: Significance in atherosclerosis

Am. Heart J.

(1987)

P. Puchois et al.

Apolipoprotein A-I containing lipoproteins in coronary artery disease

Atherosclerosis

(1987)

C.A. East et al.

Preliminary report: treatment of type III hyperlipoproteinemia with mevinolin

Metabolism

(1986)

W.J. Schneider et al.

Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows

J. Clin. Invest.

(1981)

G. Utermann et al.

Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III

Clin. Genet.

(1979)

M.S. Brown et al.

Familial type 3 hyperlipoproteinemia (Dysbetalipoproteinemia)

Cited by (54)

Therapies Targeting HDLc Levels and HDL Function
2017, The HDL Handbook: Biological Functions and Clinical Implications: Third Edition
Epidemiologic studies have shown that high density lipoprotein cholesterol (HDLc) levels are inversely associated with cardiovascular disease risk. This effect is believed to be mediated by several atheroprotective properties of HDL, including the ability to promote the reverse cholesterol transport and reduce vascular inflammation, oxidative stress and thrombosis. Thus, HDLc has been long considered a valid therapeutic target to reduce residual cardiovascular risk. Unfortunately, results obtained from large clinical trials with drugs increasing HDLc levels have been disappointing and have raised doubts on the effectiveness of this approach. With the recognition that HDLc levels may be a poor indicator of HDL atheroprotective potentials, recent strategies for drug development are focusing on enhancing HDL functions rather than HDLc levels per-se. In this chapter we will review established drugs able to raise HDLc levels as well as emerging HDL-targeting therapies currently undergoing preclinical and clinical research.
Xanthomata striata palmaris regression with fenofibrate in type III dyslipoproteinemia: A clinical report
2016, Nutrition, Metabolism and Cardiovascular Diseases
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia
2011, American Journal of Cardiology
Citation Excerpt :
Statins have been shown to decrease cholesterol and triglyceride levels by 39% to 52% and by 22% to 56%, respectively.5 Fibrates have been shown to reduce cholesterol and triglyceride levels by 40% to 45% and by 56% to 70%, respectively.6 However, neither was enough to meet the criteria for high-risk patients of published guidelines.7
Type III hyperlipoproteinemia is a rare familial disease characterized by marked elevations of serum cholesterol and triglyceride levels caused by an accumulation of remnant lipoproteins in apolipoprotein E2/E2 homozygotes. It is associated with an increased risk for premature atherosclerotic vascular disease. A 55-year-old woman was diagnosed as having type III hyperlipoproteinemia on the basis of skin lesions, serum lipid levels, lipid electrophoresis, and apolipoprotein E genotyping and stable angina pectoris on the basis of typical symptoms and treadmill exercise electrocardiographic results. After 1 year of combination therapy with atorvastatin and fenofibrate, skin xanthomata disappeared, leaving minimal remnants. In addition, there was no exertional chest pain, and treadmill exercise electrocardiographic results were negative. This finding was confirmed by coronary computed tomographic angiography. This case suggests that proper medical therapy can induce the regression of uncomplicated coronary lesions in type III hyperlipoproteinemia.
Polymorphisms in the peroxisome proliferator activated receptor α gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians
2008, Atherosclerosis
Citation Excerpt :
In vitro, activation of PPAR-α has been associated with increased lipoprotein lipase (LPL) gene transcription [3] and reduced apolipoprotein CIII (apoCIII) gene expression that can lead to increased LPL-mediated catabolism and plasma clearance of very low density lipoproteins (VLDLs) [4–6]. Fibrate drugs, which are agonists for PPARα, lower levels of plasma triglyceride (TG) and increase HDL-cholesterol concentrations in humans [7–10]. Fibrate-induced reductions in levels of apoCIII, mediated at the transcriptional level by a PPARα response element in the apoCIII gene, have been implicated in modulating the TG-lowering response to fibrates [11].
We tested whether single nucleotide polymorphisms (SNPs) in the PPARα gene (PPARA) are associated with variations in levels of plasma apolipoprotein CIII (apoCIII) levels, as well as other lipids and lipoproteins, in African-Americans and Caucasians.
We initially identified an intronic SNP (rs4253728) in PPARA that was associated with plasma apoCIII level (p < 0.05) in a subset of 435 individuals from the total study population (n = 944; 335 African-Americans and 609 Caucasians). This SNP was then genotyped in a second subset of 476 individuals (total 911 subjects with available data), and a previously described PPARA coding SNP (L162V) which was shown to be in moderate linkage disequilibrium with the intronic SNP (r² = 0.18) was genotyped in 928 subjects from the same study population. The minor allele frequencies for both SNPs were significantly lower in African-Americans compared with Caucasians (7.2% vs. 27.3% for rs4253728, 1.5% vs. 6.1% for L162V, both p < 0.0001). African-Americans had significantly lower levels of TG and apoCIII compared with Caucasians after adjusting for age, sex, body mass index (BMI), waist circumference and other baseline characteristics. However, racial differences in TG levels were attenuated after adjusting for apoCIII levels. The minor alleles for both PPARA SNPs were associated with higher TG and apoCIII levels. Race modified the associations of L162V with TG (p for interaction = 0.0056) and apoCIII (p for interaction = 0.0011). Levels of both TG and apoCIII were lower in African-American but not Caucasian homozygotes for the major allele compared with carriers of the minor allele. Similar results were obtained for the intronic SNP, but the findings were no longer significant in a model that also contained L162V.
Two PPARA SNPs, L162V and rs4253728 (intronic), are less prevalent in African-Americans than in Caucasians and in African-Americans only are associated with higher apoCIII and TG levels.
PPARα and dyslipidemia
2007, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Dyslipidemia is defined by abnormal levels of plasma lipoproteins. Several different types of dyslipidemia can be distinguished. An important group of drugs used in the treatment of dyslipidemia are the fibrates. Fibrates serve as agonists for the peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that belongs to the superfamily of nuclear hormone receptors. By binding to response elements mostly present in the promoter of target genes, PPARα governs the expression of numerous genes involved in a variety of metabolic processes. Activation of PPARα results in a reduction of plasma TG levels, which is achieved by: (1) induction of genes that decrease the availability of TG for hepatic VLDL secretion, and (2) induction of genes that promote lipoprotein lipase-mediated lipolysis of TG-rich plasma lipoproteins. The stimulatory effect of PPARα on plasma HDL levels in humans, which is opposite to what is observed in mice, appears to be mainly mediated via increased production of APOA1 and APOA2, the apolipoprotein constituents of HDL. Apart from its major actions outlined above, PPARα modulates lipoprotein metabolism in several other ways, mostly via direct up-regulation of specific PPARα target genes. By taking into account novel insights into the metabolism of plasma lipoproteins and by considering the latest information on PPARα-dependent gene regulation, a fresh perspective on the molecular mechanisms underlying the plasma lipoprotein modulating effect of PPARα is presented.
Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia
2006, Atherosclerosis
Dysbetalipoproteinemia (dysb) and familial hypercholesterolemia (FH) are two genetic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis. The co-occurrence of both metabolic abnormalities is very rare and is estimated to affect 1 individual per 2,500,000 in the general population. However, the relative contribution of these two dyslipidemias to the combined lipoprotein phenotype is unknown. The two objectives of this study were (1) to compare the in vivo kinetics of triglyceride-rich lipoprotein (TRL) apolipoprotein (apo) B48, VLDL, IDL and LDL apo B100 as well as plasma apo A-l labelled with a stable isotope (l-(5,5,5-D₃) leucine) in two subjects presenting both heterozygous FH and dysbetalipoproteinemia (FH+/dysb+), in six FH heterozygotes and in five normolipidemic controls, and (2) to examine the impact of a 6-week treatment with micronized fenofibrate 200 mg/d on apolipoprotein kinetics in FH+/dysb+. As compared with FH heterozygotes and controls, the two FH+/dysb+ subjects showed elevated TRL apo B48 and VLDL, IDL apo B100 pool sizes (PS) mainly due to lower fractional catabolic rates (FCR). Moreover, as compared with FH heterozygotes, FH+/dysb+ subjects presented lower LDL apo B100 PS due to a higher FCR. Pool size, FCR and production rate (PR) of apo A-l were higher in FH+/dysb+ subjects than in FH heterozygotes. In FH+/dysb+ subjects, fenofibrate treatment was associated with a decreased TRL apo B48 PS (−52 and −61%), VLDL apo B100 (−61 and −63%) and IDL apo B100 (−37 and −16%) and an increased FCR of TRL apo B48 (10 and 67%), VLDL apo B100 (123 and 57%) and IDL apo B100 (29 and 10%). Fenofibrate also increased LDL apo B100 PS (3 and 57%) due to an increase in PR (80 and 26%) but had divergent effects on LDL apo B100 FCR. These results indicate that the coexistence of dysbetalipoproteinemia and heterozygous FH results in a mixed lipoprotein phenotype that is intermediate between the two pure phenotypes and that fenofibrate treatment partially reverses lipoprotein abnormalities, mostly through changes in PR and FCR of apo B48- and B100-containing lipoproteins.

View all citing articles on Scopus

View full text

Research paperLipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III

Abstract

Lancet

J. Lipid Res.

Metabolism

Am. J. Med.

J. Lipid Res.

Biochim. Biophys. Acta

J. Lipid Res.

J. Biol. Chem.

Clin. Chim. Acta

Clin. Chim. Acta

J. Lipid Res.

Biochem. Biophys. Res. Commun.

Clin. Biochem.

Atherosclerosis

Pharmacol. Res. Commun.

Metabolism

J. Lipid Res.

Metabolism

J. Lipid Res.

Am. Heart J.

Am. J. Med.

Atherosclerosis

Am. Heart J.

Atherosclerosis

Metabolism

Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows

J. Clin. Invest.

Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III

Clin. Genet.

Familial type 3 hyperlipoproteinemia (Dysbetalipoproteinemia)

Research paper
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III